| CASMASCI | progen | BOC | 進(jìn)口現(xiàn)貨產(chǎn)品 | 胎牛血清 | 細(xì)胞培養(yǎng) | 提取試劑 | 轉(zhuǎn)染試劑 | 常規(guī)生化試劑 | ELISA試劑盒 | 抗體 | 細(xì)胞因子 | sigma aldrich(西格瑪) | Invitrogen(英駿) | Millipore | Abcam | CST | Roche | peprotech | prospec | pierce | BD Pharmingen | BD Biocoat | R&D | BioVision | Vector | Enzo life | eBioscience | ABR | Amresco | Cayman Chemical | 脂蛋白 | Merck | Qiagen(凱杰) | Santa cruz(三塔抗體) |
產(chǎn)品名稱:2-Methoxy estradiol
產(chǎn)品貨號:LKT M1678
產(chǎn)品規(guī)格:10 mg
Description
The compound 2-Methoxy estradiol is the metabolite of endogenous estradiol in mammalian systems and had cytostatic activity when incubated with MCF-7 tumor cells1,2. This inhibition of cell growth and other recent discoveries were found to have important implications in the potential therapeutic effects of this compound3,4. 2-ME induces microtubules disruption in cells resulting in mitotic arrest5. In prostate cancer cells, 2-ME induces G2/M arrest apoptosis6. Induction of apoptosis by 2-ME has been observed in many different tumor cell lines7-11. Apoptosis of endothelial cells by 2-ME leads to the inhibition of angiogenesis11. The antiangiogenic effects of 2-ME is effective against angiosarcoma, neuroblastoma and potentially other solid tumors12-15. Other studies on 2-ME indicate that it may be used to treat cardiovascular disease of arthritis16,17.
Specifications
Cas No. 362-07-2
Product ID M1678
Product Name 2-Methoxy estradiol
Synonym 2-Hydroxyestradol 2-methyl ether; 2-Methoxyestradiol- 17
Formula Wt. 302.41
Purity ≥98%
Solubility Soluble in DMSO or ethanol.
Store Temp -20oC
References 1. Brueggemeier RW. Kimball JG. Kraft F. Biochem Pharmacol. 33:3853-9 (1984). 2. Lottering ML. Haag M. Seegers JC. Cancer Res. 52:5926-32 (1992). 3. Schumacher G. Neuhaus P. J Cancer Res Clin Oncol. 127:405-10(2001). 4. Pribluda VS. Gubish ER Jr Lavallee TM. et al. Cancer Metastasis Rev. 19:173-9(2000). 5. D'Amato RJ. Lim CM. et al. Proc Natl Acad Sci USA. 91:3964-8 (1994). 6. Qadan LR. Perez-Stable CM. et al. Biochem Biophys Res Commun. 285:1259-66(2001). 7. Mukhopadhyay T. Roth JA. Oncogene. 14:379-84(1997). 8. Zoubine MN. Weston AP. Johnson DC. et al. nt J Oncol. 15:639-46(1996). 9. Lin HL. Liu TY. Chau GY. Liu WY. Chi CW. Cancer 89:983-94(2000). 10. Lin HL.Liu TY. Wu GW. Chi CW. Cancer 92:500-9(2001). 11. Yue TL. Wang X. Louden CS. et al. Mol Pharmacol 51:951-62(1997). 12. Klauber N. Parangi S. Flynn E. Hamel E. D'Amato RJ. Cancer Res. 57:81-6(1997). 13. Arbiser JL. Panigrathy D. Klauber N. et al. L Am Acad Dermatol. 40:925-9(1999). 14. Wassberg E. Ups J Med Sci. 104:1-24(1999). 15. Lui WY. Lin HL. Chau GY. Liu TY. Chi CW. Med Hypotheses. 55:348-50(2000). 16. Dubey RK. Jackson EK. et al. Hypertension 37:640-4(2001). 17. Josefsson E. Tarkowski A. Arthritis Rheum. 40:154-63(1997).